# Clinical Trials Data KIT - Document 61

# Knee Articular Cartilage Repair: Cartilage Autograft Implantation System Versus Conventional Microfracture

## Clinical Trial: https://clinicaltrials.gov/study/NCT01498029

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Full-thickness articular cartilage defect on the femoral condyle or trochlea greater than 2 cm2 but less than 10 cm2 in total surface area, following debridement to healthy, stable tissue.\n\* Knee mechanical axis malalignment of not more than 3 degrees either varus or valgus from neutral.\n\* Patient is fit for surgery.\n\nExclusion Criteria:\n\n\* Multifocal disease\n\* Tibial plateau lesions\n\* Patella lesions\n\* Absent menisci or meniscal tears that are unstable and cannot be successfully debrided\n\* Non-intact cruciate and collateral ligaments\n\* Inflammatory or crystalline arthropathy\n\* Systemic medication or conditions likely to compromise chondrocyte cell proliferation and differentiation, e.g. Cushing's syndrome, chemotherapy\n\* Morbid obesity (more than 150% ideal body weight)",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "21 Years",  
"stdAges": [  
"ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention anything about KIT gene mutations as either an inclusion or exclusion criterion. Therefore, based on this information alone, we \*\*cannot determine\*\* if a patient with a KIT gene mutation would be eligible or ineligible. The presence of a KIT mutation neither qualifies nor disqualifies them based on this text. Additional information would be needed.